Haematologie-Onkologie im Zentrum MVZ GmbH
- Address
- lock Available on a paid plan
Haematologie-Onkologie im Zentrum MVZ GmbH
Haematologie-Onkologie im Zentrum MVZ GmbH is a specialized clinical research center with extensive expertise in oncology and hematology clinical trials. The center demonstrates particular strength in breast cancer research across all stages of disease, from early-stage neoadjuvant studies to advanced metastatic disease, alongside significant involvement in hematological malignancies.
- Comprehensive breast cancer research including hormone receptor-positive, HER2-negative, triple-negative, and HER2-positive subtypes with novel targeted therapies and immunotherapies
- Advanced treatment strategies for hormone receptor-positive breast cancer utilizing CDK4/6 inhibitors, selective estrogen receptor degraders (SERDs), and PI3K/AKT pathway inhibitors
- Hematological malignancies including chronic lymphocytic leukemia, polycythemia vera, and Hodgkin lymphoma with focus on targeted and combination therapies
- Gastrointestinal oncology trials investigating novel immunotherapy combinations in advanced and metastatic disease settings
The center's research portfolio emphasizes precision medicine approaches with biomarker-driven patient selection, including studies targeting specific genetic mutations such as BRCA1/2, ESR1, and PIK3CA/AKT1/PTEN alterations. Their participation in large-scale international phase II and III trials demonstrates capability in evaluating novel therapeutic agents including antibody-drug conjugates, PARP inhibitors, and next-generation endocrine therapies. The center contributes to advancing treatment de-escalation strategies and risk-adapted therapeutic approaches, particularly in early breast cancer settings where circulating tumor DNA monitoring guides personalized treatment decisions.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Top 2 of 3 therapeutic areas and 15 of 75 IMPs, ranked by number of trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Top 40 of 75 compounds, ranked by number of trials.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 15 by active trials.
lock +14 more on a paid plan
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
- 1AstraZeneca AB5trials
lock +6 more on a paid plan
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 2 161 other sites in Germany
Therapeutic Area Benchmark — Germany
Select a therapeutic area to compare against other sites in Germany.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Germany
Market Share
Country: Germany
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Haematologie-Onkologie im Zentrum MVZ GmbH
lock Showing 1 of 35 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| A Phase 2, randomized, multicenter, open-label neoadjuvant study evaluating zanidatamab in combination with chemotherapy in participants with HER2-positive breast cancer | Jazz Pharmaceuticals Ireland Limited | Phase II | Not Yet Recruiting | Mar 2026 | — |
IMP list
lock Showing 1 of 75 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Anastrozole | 8 | Unknown | 2019-05-22 | 2025-12-18 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.